Brief: Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection For IgA Nephropathy Program
14/12/2022 13:04
Dec 14 (Reuters) - Selecta Biosciences Inc SELB.O :
* SELECTA BIOSCIENCES ANNOUNCES NEXT GENERATION IGA PROTEASE
CLINICAL CANDIDATE SELECTION FOR IGA NEPHROPATHY PROGRAM
* SELECTA BIOSCIENCES INC - SELECTION OF IGA PROTEASE
CANDIDATE
TRIGGERS PAYMENT OF $1.6 MILLION TO IGAN BIOSCIENCES
Source text for Eikon: ID:nGNX49VQhR
Further company coverage: SELB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cartesian Therapeutics
See all newsBrief: Cartesian Therapeutics Announces Additional Retreatment Data For Descartes-08 Highlighting Deep And Durable Responses In Patients With Myasthenia Gravis
Cartesian Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cartesian Therapeutics Q2 net income steady
Brief: Cartesian Therapeutics Inc Q2 Net Income USD 15.769 Million
Cartesian Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview